In March 2025, the company announced new designs for just a immediate-to-client offering of its Wegovy weight loss drug. The company proven a fresh pharmacy, identified as NovoCare, which would demand prospects $499 monthly for usage of the drug, below 50 percent the expense of the drug as a result of other pharmaceutical distribution networks.[fif